DAIC Articles

Sep 24, 2019 | DAIC Articles
Medtronic Launches Evolut Pro+ TAVR System

September 24, 2019 – Medtronic announced U.S. Food and Drug Administration (FDA) approval and U.S. launch of the Evolut Pro+ transcatheter aortic valve replacement (TAVR) system. The new-generation Medtronic TAVR system builds off the self-expanding, supra-annular Evolut TAVR platform. The Evolut Pro+ TAVR System includes four valve sizes with an external pericardial tissue wrap that provides advanced […]

Sep 23, 2019 | DAIC Articles
Polypill Drops BP, LDL Cholesterol in a Disadvantaged US Population

Use of a fixed-dose combination of a statin and three antihypertensives led to greater reductions in LDL cholesterol and systolic blood pressure than did usual care in an underserved, predominantly African-American community in Alabama, new randomized data show.

Sep 23, 2019 | DAIC Articles
FDA Grants Shockwave Medical Breakthrough Status for Coronary Intravascular Lithotripsy

September 3, 2019 — Shockwave Medical Inc. has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its Shockwave intravascular lithotripsy (IVL) system with the Shockwave C2 Coronary IVL Catheter. The device is currently the subject of an Investigational Device Exemption (IDE) study called DISRUPT CAD III.

Sep 23, 2019 | DAIC Articles
Complete Revascularization Superior to Culprit Lesion-only Intervention

September 10, 2019 — An international randomized trial has shown that complete revascularization reduces major cardiovascular events compared to culprit lesion-only percutaneous coronary intervention (PCI). Late breaking results of the COMPLETE trial were presented in a Hot Line Session at the European Society of Cardiology (ESC)Congress 2019 together with the World Congress of Cardiology, and […]

Sep 19, 2019 | DAIC Articles
Early ICD Use Prolongs Survival After Coronary Stenting

September 18, 2019 — Early use of an implantable cardioverter-defibrillator (ICD) after primary coronary intervention lengthens survival in patients at high risk of death after ST-segment elevation myocardial infarction (STEMI). The late-breaking results from the DAPA trial were presented in a Hot Line Session at the European Society of Cardiology (ESC) Congress 2019, Aug. 31-Sept. […]

Sep 18, 2019 | DAIC Articles
New ESC Guideline Provides Class 1 Recommendation for Coronary CTA

September 17, 2019 — The European Society of Cardiology (ESC) published new guidelines on the diagnosis and management of chronic coronary syndromes (CCS), which classifies computed tomography angiography (CTA) as a Class 1 recommendation for diagnosing CAD in symptomatic patients. The document, which is a continuation of the 2013 stable coronary artery disease (CAD) guidelines, […]

Sep 17, 2019 | DAIC Articles
FDA Clears Artis Icono Family of Angiography Systems from Siemens Healthineers

September 17, 2019 — The U.S. Food and Drug Administration (FDA) has cleared the Artis icono, a high-precision family of angiography systems from Siemens Healthineers that permit a wide range of minimally invasive procedures to be performed in a single interventional suite.

Sep 16, 2019 | DAIC Articles
Corvia Medical and physIQ Partner in Global Phase 3 Heart Failure Device Clinical Trial

September 12, 2019 — Corvia Medical has sponsored and is actively enrolling patients in a heart failure (HF) device trial that, in addition to measuring traditional heart failure endpoints, includes collecting and analyzing biosensor data with physIQ’s continuous remote monitoringplatform. The clinical trial is designed to evaluate the clinical efficacy of Corvia’s InterAtrial Shunt Device […]

Sep 9, 2019 | DAIC Articles
Integrated STEMI Activation System at a Rural Hospital Improves Door-to-Balloon Times

Primary percutaneous coronary intervention (PCI) is the preferred treatment for acute ST-segment elevation myocardial infarction (STEMI). Previous studies have shown a strong association between urgent performance of primary PCI, as assessed in terms of the door-to-balloon time (D2B), the interval from the patient’s arrival at the hospital to inflation of the balloon to restore flow, […]

Sep 9, 2019 | DAIC Articles
Superiority of Orsiro Over Xience Stent Demonstrated in STEMI Patients

September 5, 2019 — Biotronik’s ultrathin Orsiro stent demonstrated superiority over Xience with respect to target lesion failure (TLF) at 12 months, according to newly released data from the BIOSTEMI trial.1 At the European Society of Cardiology (ESC) 2019 Congress, Aug. 31-Sept. 4 in Paris, France, Juan Fernando Iglesias, M.D., Ph.D., Geneva University Hospitals, Geneva, […]